Tenaya Therapeutics, Inc. (TNYA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 61.61M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.58M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -105.86M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $61.61M | (m) | $9.58M | $-105.86M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $62.37M | (m) | $11.51M | $-85.86M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $68.61M | (m) | $13.05M | $-93.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $72.50M | (m) | $14.06M | $-97.21M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $77.48M | (m) | $15.03M | $-102.98M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $82.76M | (m) | $16.01M | $-109.72M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $86.74M | (m) | $16.50M | $-115.95M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $90.92M | (m) | $16.69M | $-122.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $93.66M | (m) | $16.80M | $-126.95M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $97.49M | (m) | $16.02M | $-131.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $98.04M | (m) | $15.31M | $-131.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $100.92M | (m) | $14.55M | $-134.30M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $101.59M | (m) | $13.71M | $-134.68M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $95.99M | (m) | $12.89M | $-128.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $94.54M | (m) | $11.47M | $-125.62M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $89.74M | (m) | $9.33M | $-117.23M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $78.93M | (m) | $7.12M | $-104.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $68.96M | (m) | $4.61M | $-90.86M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $54.39M | (m) | $2.95M | $-72.81M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $31.10M | (m) | $741.00K | $-38.91M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |